Swarming cancer with personalised T cells
Unlocking the full potential of Cancer and viral vaccines
Swarm’s platform is designed to unlock the full potential of personalised T cell therapies.
We deliver cell therapies that are highly targeted, phenotypically optimized, cost efficient and durable. In combination with In Vivo Priming this ensures that each therapy is harnessing the unique biology of the patient's tumour and maximizing potential therapeutic power.
Our collaborators in advancing cancer therapy
Investing in next generation of T cell therapies
Swarm is currently backed by Delin Ventures – a specialized venture fund focusing on investment with T cell therapy.
Partnerships
Our business builds through partnerships, and we welcome discussions with new investors and potential partners. Get in touch to discuss opportunities.
